UCSF Seeks FDA Approval for Groundbreaking In Utero Gene Therapy Trial
A team at UCSF has taken a significant step toward pioneering a trial for in utero gene therapy aimed at treating a rare lysosomal storage disorder by submitting an application to the FDA.
The University of California, San Francisco (UCSF) is making strides in the field of genetic medicine. The team has recently submitted an application to the FDA for approval to conduct a small trial focused on in utero gene therapy.
This innovative approach targets a rare lysosomal storage disorder, which poses significant health challenges. The potential of such a therapy could change the landscape of treatment for genetic diseases.
As the application process unfolds, the implications of this research could be profound, offering hope for early intervention in genetic disorders before birth.